Outcomes and Costs of Favipiravir, Molnupiravir, Remdesivir and Andrographis paniculata during the COVID-19 Outbreak, Kut Chum District, Yasothon Province


  • Chanchai Booncherd Consumer Protection and Pharmaceutical Public Health Division, Khudchum Hospital
  • Sothara Anugoolpracha Consumer Protection and Pharmaceutical Public Health Division, Thai Charoen Hospital, Thailand


molnupiravir, favipiravir, remdesivir, COVID, cost


The treatment of COVID-19 with medications is still a subject that requires ongoing monitoring and further research to confirm the efficacy and effectiveness of the drugs. The results and costs of COVID-19 treatment medications in the hospital’s database can be utilized in decision-making for treatment planning and hospital policy. However, there is still a lack of analysis regarding the results and costs of these medications. The objective of this study was to evaluate the efficacy and cost of favipiravir, molnupiravir, remdesivir, and Andrographis paniculata during the COVID-19 outbreak. A retrospective study was conducted on the treatment data of COVID-19 patients at Kudchum Hospital, Yasothon province, between March and June 2022 (2565 B.E.). The study analyzed clinical outcomes and the cost of medications, as well as the total cost, in patients infected with COVID-19 who received favipiravir, molnupiravir, remdesivir, and Andrographis paniculata. The analysis included patients who received outpatient treatment with self-isolation at home (out-patient with self isolation/home isolation, OPSI/HI) and patients treated with hospital admission. The results of the treatment were analyzed using multiple logistic regression, and the cost of treatment was assessed using the Kruskall-Wallis test. It was found that the majority of patients were female with an average age of 48 years. A total of 4,114 patients received outpatient self-isolation (OPSI) and home isolation (HI) treatment. Fifty-four percent of them were administered favipiravir, and among the 21 admitted patients, the majority also received favipiravir. When controlling for the influence of gender, age, absence of comorbidities, and risk factors such as obesity and asthma, it was found that receiving favipiravir in OPSI and HI did not significantly affect the improvement rate compared to those receiving the placebo (OR = 1.011, 95% CI 0.381 – 1.230). The average cost of favipiravir per person per day for admitted patients was lower than the average cost of remdesivir (median of 2,883.75 THB vs. 23,804.14 THB). When calculating the proportion of total drug costs, the cost of molnupiravir accounts for 0.14%, the cost of the placebo (favipiravir) accounts for 3.87%, and the cost of favipiravir accounts for 95.99%. In conclusion, the results of this study indicated that the outcomes of the drugs molnupiravir and favipiravir in treating COVID-19 did not differ significantly in the group of patients without or with mild symptoms. However, favipiravir had a lower drug cost compared to remdesivir for admitted patients.


Download data is not yet available.


กรมควบคุมโรค. สถานการณ์ไวรัสโคโรนา 2019 ทั่วโลก [อินเทอร์เน็ต]. [สืบค้นเมื่อ 2 ส.ค. 2564]. แหล่งข้อมูล: https://ddcportal.ddc.moph.go.th/portal/apps/opsdashboard/index.html#/20f3466e075e45e5946aa87c96e8ad65

กรุงเทพมหานคร. สถานการณ์ไวรัสโคโรนา 2019 กรุงเทพมหานคร [อินเทอร์เน็ต]. [สืบค้นเมื่อ 13 ส.ค. 2564]. แหล่งข้อมูล: http://www.prbangkok.com/th/ covid-today/view/MDY1cDBzNnM0NHIyb3Ezc3E2NnEyNDk0cDRyOTQzcjQxODE2Mg.

Cunningham JW, Vaduganathan M, Claggett BL. Clinical outcomes in young US adults hospitalized with COVID-19. JAMA Intern Med 2021;181(3):379-81.

สมคิด แก้วสนธิ, ภิรมย์ กมลรัตนกุล. หลักการและแนวคิด การประยุกต์เศรษฐศาสตร์คลินิกในระบบโรงพยาบาล. เศรษฐศาสตร์สาธารณสุข: การวิเคราะห์และประเมินผล บริการสาธารณสุข. พิมพ์ครั้งที่ 1. กรุงเทพมหานคร: คณะเศรษฐศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย; 2534.

กรมการแพทย์. แนวทางเวชปฏิบัติ การวินิจฉัย ดูแลรักษา และป้ องกันการติดเชื้อในโรงพยาบาล กรณีโรคติดเชื้อไวรัส โคโรนา 2019 [อินเทอร์เน็ต]. [สืบค้นเมื่อ 2 ส.ค. 2564]. แหล่งข้อมูล: https://covid19.dms.go.th/backend/Content/Content_File/Covid_Health/Attach/ 25640625085440AM_CPG_COVID_v.15_n% 2020210625.pdf)

US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA authorizes additional oral antiviral for treatment of covid-19 in certain adults. US Food & Drug Administration [Internet]. 2021 [cited 2022 Aug 19]. Available from: https://www.fda.gov/newsevents/press-announcements/coronavi - rus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain

Mishima E, Anzai N, Miyazaki M, Abe T. Uric Acid Elevation by favipiravir, an antiviral drug. Tohoku J Exp Med 2020;251(2):87-90.

Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, reandomized controlled clinical trial. Front Pharmacol 2021; 2;(12):683296.

Merck. Merck and Ridgeback Biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral therapeutic for the treatment of mild-to-moderate COVID-19 [Internet]. [cited 2023 Dec 9]. Available from: https://www. merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-ofmild-to-moderate-covid-19/?fbclid=IwAR3HF7BcigU9RZwEa-KpNt8Uk5Yx91aTotAnEUtiQ7Don7O-xBW_iOzyd3E

Merck. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study [Internet]. [cited 2023 Dec 9]. Available from: https://www.merck.com/news/ merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalizationor-death-by-approximately-50-percent-compared-toplacebo-for-patients-with-mild-or-moderat

อัมพร เบญจพลพิทักษ์, ขวัญชัย วิศิษฐานนท์, ธิติ แสวงธรรม, เทวัญ ธานีรัตน์, กุลธนิต วนรัตน์. รายงานสังเขป ผลการใช้ยาฟ้ าทะลายโจรในการรักษาผู้ป่ วย COVID-19. วารสารการแพทย์แผนไทยและการแพทย์ทางเลือก 2564; 23(19):229-33.

Miethke-Morais A, Cassenote A, Piva H, Tokunaga E, Cobello V, Gonçalves FAR, et al. COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors. Braz J Infect Dis 2021; 25(4):1-9.

สมจิตร ทองแย้ม. ต้นทุนต่อหน่วยบริการผู้ป่วยใน: หอผู้ป่วย แยกโรคแพร่กระจายเชื้อทางอากาศ สถาบันบำราศนราดูร ปีงบประมาณ 2558. วารสารสถาบันบำราศนราดูร 2562;1(1):1-12.



How to Cite

บุญเชิด ช., & อนุกูลประชา โ. (2024). Outcomes and Costs of Favipiravir, Molnupiravir, Remdesivir and Andrographis paniculata during the COVID-19 Outbreak, Kut Chum District, Yasothon Province. Journal of Health Science of Thailand, 33(1), 108–119. Retrieved from https://thaidj.org/index.php/JHS/article/view/13008



Original Article (นิพนธ์ต้นฉบับ)